Sitaxsentan therapy for pulmonary arterial hypertension.
By R. Barst, D. Langleben, A. Frost, E. Horn, R. Oudiz, S. Shapiro, V. McLaughlin, N. Hill, V. Tapson, I. Robbins and 4 more. American Journal of Respiratory and Critical Care Medicine, 2004
741 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/06f0d28ead886fdc65b0ce4432d048d50944f4d9
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- O. Kowal-Bielecka
- A. Tyndall
- J. Avouac
- J. Seibold
- D. Furst
- P. Clements
- I. Földvari
- U. Müller-Ladner
Citations in the corpus
- EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR) (2009, background): “39 The improvement was even greater in a STRIDE-1 subgroup of PAH patients being in WHO class III or IV, suggesting that patients with more severe PAH may achieve the greatest benefit from sitaxentan therapy, 48 see supplementary table 3 available online only.”
- Tadalafil Therapy for Pulmonary Arterial Hypertension (2009, neutral): “Class II 23 (28) 29 (35) 24 (30) 28 (34) 26 (33)”